ARGX vs. HALO: argenx vs. Halozyme Therapeutics Stock Comparison
How do argenx (ARGX) and Halozyme Therapeutics (HALO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
argenx (ARGX) and Halozyme Therapeutics (HALO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Halozyme Therapeutics (HALO) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ARGX | HALO |
|---|---|---|
| Name | argenx SE American Depositary Receipt | Halozyme Therapeutics Inc. |
| Country/Region | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 58.31 billion USD | 11.81 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 18, 2017 | March 16, 2004 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ARGX | HALO |
|---|---|---|
| Total Return (1Y) | 11.91% | 50.94% |
| Total Return (3Y, Annualized) | 25.68% | 41.08% |
| Total Return (5Y, Annualized) | 24.22% | 21.68% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ARGX | HALO |
|---|---|---|
| Volatility (1Y, Annualized) | 37.87% | 41.19% |
| Beta (5Y) | 0.45 | 0.96 |
| Max Drawdown (5Y) | -38.20% | -49.06% |
| Avg. Volume (3M) | 359.84K | 2.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ARGX | HALO |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 1.13 |
| Sortino Ratio (1Y) | 0.31 | 1.78 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Halozyme Therapeutics (HALO) earns 216.38% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both argenx (ARGX) at 31.73% and Halozyme Therapeutics (HALO) at 26.93% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both argenx (ARGX) at 36.27% and Halozyme Therapeutics (HALO) at 59.84% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ARGX | HALO |
|---|---|---|
| ROE (TTM) | -- | 216.38% |
| ROA (TTM) | -- | 22.42% |
| Net Margin (TTM) | 31.73% | 26.93% |
| Operating Margin (TTM) | 36.27% | 59.84% |
| Gross Margin (TTM) | 59.84% | 77.74% |
Growth
Revenue Growth
argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Halozyme Therapeutics (HALO) at 37.55% is closer to the peer norm — faster top-line expansion for ARGX.
EPS Growth
Both argenx (ARGX) at 53.13% and Halozyme Therapeutics (HALO) at -25.36% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | ARGX | HALO |
|---|---|---|
| Revenue Growth (YoY) | 89.64% | 37.55% |
| Revenue Growth (3Y CAGR) | 116.25% | 28.38% |
| EPS Growth (YoY) | 53.13% | -25.36% |
| EPS Growth (3Y CAGR) | -- | 21.14% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Halozyme Therapeutics (HALO) shows current ratio of 3.88 against its industry benchmark, while argenx (ARGX) has no reading this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: argenx (ARGX) carries debt-to-equity ratio of 0.01 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
Financial Strength Metrics
| Metric | ARGX | HALO |
|---|---|---|
| Current Ratio (MRQ) | -- | 3.88 |
| Debt / Equity (MRQ) | 0.01 | -- |
| Net Debt / EBITDA | -2.70 | 1.90 |
Dividends
Dividend Yield (TTM)
Neither argenx (ARGX) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither argenx (ARGX) nor Halozyme Therapeutics (HALO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ARGX | HALO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both argenx (ARGX) at 32.12 and Halozyme Therapeutics (HALO) at 25.91 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both argenx (ARGX) at 9.86 and Halozyme Therapeutics (HALO) at 6.55 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile argenx (ARGX) reports 172.23, ranking against industry peers normally.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
Valuation Metrics
| Metric | ARGX | HALO |
|---|---|---|
| P/E Ratio (TTM) | 32.12 | 25.91 |
| P/S Ratio (TTM) | 9.86 | 6.55 |
| P/B Ratio (MRQ) | 172.23 | -213.67 |
| Free Cash Flow Yield (TTM) | -- | 3.48% |